Ballicules.com

Buprenorphine/ naloxone

SUBOXONE

What it isBuprenorphine partial mu agonist plus poorly absorbed sublingual naloxone; maintenance treatment for opioid use disorder.

Why this oneThe naloxone is a misuse deterrent: negligible sublingually, but it precipitates withdrawal if the product is dissolved and injected.

What limits itStarting it too soon after a full agonist precipitates withdrawal. Benzodiazepines and other sedatives still increase respiratory risk.

FDA label

FDA dosingPopulationStartTargetMax
Opioid dependence (induction)Adults (short-acting opioid dependence)Day 1: up to 8 mg/2 mg (divided doses); Day 2: up to 16 mg/4 mg QD16 mg/4 mg on Day 2
Opioid dependence (maintenance)AdultsTitrate from induction dose4 mg/1 mg to 24 mg/6 mg QD24 mg/6 mg QD

Renal Undefined

Hepatic Not recommended in severe hepatic impairment; may not be appropriate in moderate hepatic impairment

Instructions

Cautions

Adverse reactions

Pregnancy Limited data do not indicate increased malformation risk from buprenorphine; prolonged use can cause neonatal opioid withdrawal syndrome; dose adjustments may be needed.

Lactation Buprenorphine present in low levels in human milk; oral naloxone absorption limited; monitor infant.

NO BOXED WARNINGS

Classes and tags

Clinical profile

Direct muscarinic antagonism0 / 4

Mechanism of action: Buprenorphine/ naloxone ballicule

Buprenorphine/ naloxone ballicule: receptor binding, kinetics and half-life diagram

Open Buprenorphine/ naloxone in the interactive console ↗

Memory aids: mascots and interaction avatars

Buprenorphine/ naloxone SUBOXONE mascot mnemonic cartoon
“Sub + Boxed Nalox”
pinpoint pupils → opioid
dilated pupils → opioid blocker
SUBmarine periscope on bumper car

Open Buprenorphine/ naloxone in the interactive console ↗